Regarding lysine demethylases, inhibitors of KDM1A are in clinical trials for refractory cancers and Alzheimer’s disease, while inhibitors of KDM4 and KDM4C are only being studied for refractory cancers, and drug discovery in this field may be realized in the near future. This evidence concerns the gene KDM4C and early-onset autosomal dominant Alzheimer disease.